Fig. 3.

Combination of dasatinib, fluvastatin and pazopanib efficiently reduced the viability of MDA-MB-231. (A) Combination therapy using dasatinib, fluvastatin, and pazopanib for MDA-MB-231. (i) Fluvastatin in combination with dasatinib. (ii) Pazopanib with dasatinib. (iii) Pazopanib with fluvastatin. Cells were treated with inhibitors for 4 days and viability was measured by MTT assay. Data represents mean and standard deviation of triplicate. Data is a representative of at least three independent experiments. (B) Colony formation reduced by the combination of dasatinib, fluvastatin, and pazopanib in MDA-MB-231. (i) MDA-MB-231 and (ii) MCF-7 cells were treated with the combination of inhibitors (dasa: dasatinib, fluva: fluvastatin, pazo: pazopanib) for 7 or 10 days. Colony formation was determined by staining with crystal violet. Data is representative of three independent experiments.